Published in PLoS One on September 30, 2009
A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med (2005) 21.48
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet (2005) 18.59
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature (2005) 18.43
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 17.41
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med (2007) 8.18
Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem (2005) 5.58
Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood (2006) 3.88
JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood (2006) 3.37
TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia (2007) 2.49
Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood (2008) 2.37
18F-FLT PET in hematologic disorders: a novel technique to analyze the bone marrow compartment. J Nucl Med (2006) 2.18
Suppression of Fas-FasL coexpression by erythropoietin mediates erythroblast expansion during the erythropoietic stress response in vivo. Blood (2006) 2.16
Polycythemia vera: a comprehensive review and clinical recommendations. Mayo Clin Proc (2003) 1.79
Complications of splenectomy. Am J Med (2008) 1.77
Large, chronic doses of erythropoietin cause thrombocytopenia in mice. Blood (1992) 1.53
A role for JAK2 mutations in myeloproliferative diseases. Annu Rev Med (2008) 1.47
The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype. Eur J Haematol (2007) 1.33
SURGERY IN POLYCYTHEMIA VERA. N Engl J Med (1963) 1.05
Splenectomy in chronic myeloid leukemia and myelofibrosis with myeloid metaplasia. Blood Rev (2000) 0.87
The role of Janus Kinase 2 V617F mutation in extramedullary hematopoiesis of the spleen in neoplastic myeloid disorders. Mod Pathol (2007) 0.85
Spleen sizing by ultrasound in polycythaemia and thrombocythaemia: comparison with SPECT. Br J Haematol (1997) 0.85
An inhibitor of Janus kinase 2 prevents polycythemia in mice. Biochem Pharmacol (2009) 0.82
Results of a prospective randomized trial of early splenectomy in chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Cancer (1984) 0.81
Modern treatment strategies in polycythemia vera. Semin Hematol (2003) 0.78
Splenectomy for massive splenomegaly of polycythemia vera. Am J Surg (2004) 0.78
Splenectomy does not enhance engraftment of DLA-nonidentical marrow transplants. Exp Hematol (1993) 0.77
Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov (2013) 2.43
Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors. Sci Transl Med (2010) 2.13
Beta-Adrenergic receptors, diet-induced thermogenesis, and obesity. J Biol Chem (2003) 1.95
An Msh2 point mutation uncouples DNA mismatch repair and apoptosis. Cancer Res (2004) 1.81
The binding site for channel blockers that rescue misprocessed human long QT syndrome type 2 ether-a-gogo-related gene (HERG) mutations. J Biol Chem (2001) 1.60
NXP-2 association with SUMO-2 depends on lysines required for transcriptional repression. Proc Natl Acad Sci U S A (2006) 1.59
Hypothalamic orexin stimulates feeding-associated glucose utilization in skeletal muscle via sympathetic nervous system. Cell Metab (2009) 1.51
Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancer. Cancer Res (2009) 1.41
Human selenium binding protein-1 (hSP56) interacts with VDU1 in a selenium-dependent manner. Biochem Biophys Res Commun (2008) 1.16
Zebrafish unplugged reveals a role for muscle-specific kinase homologs in axonal pathway choice. Nat Neurosci (2004) 1.15
Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells. Prostate (2006) 1.09
PDK1 attenuation fails to prevent tumor formation in PTEN-deficient transgenic mouse models. Cancer Res (2011) 0.99
Control of cell growth and survival by enzymes of the fatty acid synthesis pathway in HCT-116 colon cancer cells. Clin Cancer Res (2008) 0.96
Novel roles for MLH3 deficiency and TLE6-like amplification in DNA mismatch repair-deficient gastrointestinal tumorigenesis and progression. PLoS Genet (2008) 0.91
MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation. Invest New Drugs (2011) 0.87
Efficacious intermittent dosing of a novel JAK2 inhibitor in mouse models of polycythemia vera. PLoS One (2012) 0.86
Fluorinated piperidine acetic acids as gamma-secretase modulators. Bioorg Med Chem Lett (2009) 0.84
An inhibitor of Janus kinase 2 prevents polycythemia in mice. Biochem Pharmacol (2009) 0.82
Evidence of mTOR Activation by an AKT-Independent Mechanism Provides Support for the Combined Treatment of PTEN-Deficient Prostate Tumors with mTOR and AKT Inhibitors. Transl Oncol (2012) 0.81
Roscovitine, olomoucine, purvalanol: inducers of apoptosis in maturing cerebellar granule neurons. Biochem Pharmacol (2004) 0.80
Lack of MSH2 involvement differentiates V(D)J recombination from other non-homologous end joining events. Nucleic Acids Res (2005) 0.78
Development of a cell-based assay for measurement of c-Met phosphorylation using AlphaScreen technology and high-content imaging analysis. J Biomol Screen (2009) 0.78
Real-time bioluminescence imaging of polycythemia vera development in mice. Biochim Biophys Acta (2009) 0.78
Trophic agents that prevent neuronal apoptosis activate calpain and down-regulate CaMKIV. J Neurochem (2002) 0.77
Genes essential for cell viability that are linked to tumor suppressor genes play a role in cancer susceptibility. Cell Cycle (2010) 0.75
Reduced blockade by extracellular Mg(2+) is permissive to NMDA receptor activation in cerebellar granule neurons that model a migratory phenotype. J Neurochem (2010) 0.75
A school-based intervention for diabetes risk reduction. N Engl J Med (2010) 0.75
The discovery of tricyclic pyridone JAK2 inhibitors. Part 1: hit to lead. Bioorg Med Chem Lett (2010) 0.75